Literature DB >> 9828219

Identification of glutathione S-transferase isozymes and gamma-glutamylcysteine synthetase as negative acute-phase proteins in rat liver.

T M Buetler1.   

Abstract

Because acute infection and inflammation affect drug metabolism and drug-metabolizing enzymes, the effect of the acute-phase response on the expression of glutathione S-transferase (GST) isoenzymes, glutathione synthesis, and several antioxidant enzymes was investigated. Hepatic expression of GST isozymes, positive and negative acute-phase reactants, and antioxidant enzymes were determined by Northern blotting and hybridization with gene-specific oligonucleotide probes after lipopolysaccharide treatment of rats. Lipopolysaccharide caused the expected acute-phase response as judged by the increased expression of positive and decreased expression of negative acute-phase proteins. The messenger RNA (mRNA) expression of the major hepatic rat GST isozymes A1, A2, A3, M1, and M2 was decreased 50% to 90%. Total hepatic GST activity toward 1-chloro-2,4-dinitrobenzene was also significantly decreased. mRNA expression of gamma-glutamylcysteine synthetase (GCS) large subunit and catalase was reduced by approximately 60%. GCS enzyme activity was also decreased, resulting in a 35% decrease in the hepatic content of reduced glutathione 4 days after lipopolysaccharide challenge. Mn-Superoxide dismutase expression was increased 13-fold, and thioredoxin level was elevated 3-fold after lipopolysaccharide challenge. The expression of all parameters determined returned to near control levels 7 days after treatment. Together, these data show that GSTs and GCS are negative acute-phase proteins and that decreased GCS activity results in a decrease in hepatic glutathione content. Thus, in addition to the phase I drug-metabolizing enzymes known to be decreased during the acute-phase response, some phase II enzymes involved in the elimination of xenobiotics and carcinogens are also decreased.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828219     DOI: 10.1002/hep.510280615

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Identification of a short form of ubiquitin-specific protease 3 that is a repressor of rat glutathione S-transferase gene expression.

Authors:  Richard Whalen; Xiangdang Liu; Thomas D Boyer
Journal:  Biochem J       Date:  2006-03-01       Impact factor: 3.857

2.  Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS.

Authors:  H Nakamura; S C De Rosa; J Yodoi; A Holmgren; P Ghezzi; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  Mechanism of negative regulation of rat glutathione S-transferase A2 by the cytokine interleukin 6.

Authors:  Susan H Voss; Richard Whalen; Thomas D Boyer
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

4.  Decreased expression levels of rat liver glutathione S-transferase A2 and albumin during the acute phase response are mediated by HNF1 (hepatic nuclear factor 1) and IL6DEX-NP.

Authors:  Richard Whalen; Susan H Voss; Thomas D Boyer
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

5.  Chronic hypoxia differentially increases glutathione content and gamma-glutamyl cysteine synthetase expression in fetal guinea pig organs.

Authors:  Chien Oh; Yafeng Dong; Christopher Harman; Hugh E Mighty; Jerome Kopelman; Loren P Thompson
Journal:  Early Hum Dev       Date:  2007-05-18       Impact factor: 2.079

6.  Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells.

Authors:  R Bertini; O M Howard; H F Dong; J J Oppenheim; C Bizzarri; R Sergi; G Caselli; S Pagliei; B Romines; J A Wilshire; M Mengozzi; H Nakamura; J Yodoi; K Pekkari; R Gurunath; A Holmgren; L A Herzenberg; L A Herzenberg; P Ghezzi
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.